One Turn Open the globe →

Health · Silver Spring, Maryland · United States of America ·

FDA orders eye-risk warnings on GLP-1 drugs

Reported by 1 outlet · under-reported · first reported Nov 9, 7:00 PM ET

The FDA told makers of semaglutide and tirzepatide to warn about a rare optic nerve disorder that can cause permanent vision loss.

Why it matters

Millions use these drugs for diabetes and weight loss.

Background

These drugs are sold under brands such as Ozempic and Mounjaro.

The story so far

  1. FDA adds eye risk warning to GLP-1 drugs
  2. FDA orders eye-risk warnings on GLP-1 drugs

Follow the whole story →

Sources

This summary was written automatically from the reporting linked above; follow the sources for the full story. How One Turn works.

See it on the globe →All of Nov 11's stories

More on health